These are the LLMs that caught our attention in 2025—from autonomous coding assistants to vision models processing entire codebases.
The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
Poppy and Nick O'Hagan discuss the benefits of theatrical windows and community in the age of Netflix and A24, launching with director Richard Hawkins' Tallinn-premiering title, and their next ...
Bowing in Tallinn’s official competition, “Think of England” is the long-awaited sophomore pic of BAFTA-nominated British writer-director Richard Hawkins. If his directorial debut “Everything” (2004) ...
The percentage of Americans who believe the Democratic Party is “out of touch” has increased by double-digits over the last decade, with 70% indicating the party is disconnected from the issues that ...
In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...
Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...
We recently published 10 Big Names With Explosive Growth. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best performers on Wednesday. Recursion Pharmaceuticals jumped by 16.44 percent on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results